We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients

This study is not yet open for participant recruitment.
Verified June 2017 by Jing Li, Affiliated Hospital of Hebei University
Sponsor:
ClinicalTrials.gov Identifier:
NCT03177408
First Posted: June 6, 2017
Last Update Posted: June 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Jing Li, Affiliated Hospital of Hebei University
  Purpose
This study evaluated the association between HMGB1 and diastolic dysfunction in hypertensive patients. HMGB1 level were tested in all patients, and diastolic function determined by echocardiographic.

Condition
Diastolic Dysfunction Hypertension Inflammation

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients

Further study details as provided by Jing Li, Affiliated Hospital of Hebei University:

Primary Outcome Measures:
  • Differences of HMGB1 levels between hypertensive patients with and without diastolic dysfunction [ Time Frame: on the day of admission ]
    Blood samples of all individuals are collected on the day of admission and HMGB1 levels are tested. Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.


Secondary Outcome Measures:
  • Differences of HMGB1 levels between grades of diastolic dysfunction [ Time Frame: on the day of admission ]
    Blood samples of all individuals are collected on the day of admission and HMGB1 levels are tested. Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.


Estimated Enrollment: 100
Anticipated Study Start Date: August 15, 2017
Estimated Study Completion Date: December 31, 2017
Estimated Primary Completion Date: December 31, 2017 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study sample is recruited from the patients examined in the physical examination center of our hospital.
Criteria

Inclusion Criteria:

All of the hypertensive patients in both diastolic dysfunction and control groups were either newly diagnosed or were aware of hypertension without using any pharmacotherapy.

Exclusion Criteria:

Individuals already under treatment for hypertension were not include.

  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Jing Li, Doctor, Affiliated Hospital of Hebei University
ClinicalTrials.gov Identifier: NCT03177408     History of Changes
Other Study ID Numbers: 2017032901
First Submitted: April 16, 2017
First Posted: June 6, 2017
Last Update Posted: June 6, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jing Li, Affiliated Hospital of Hebei University:
Diastolic Dysfunction
Hypertension
HMGB1

Additional relevant MeSH terms:
Hypertension
Inflammation
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes